Posted by Michael Wonder on 08 Nov 2021
Seelos Therapeutics announces FDA grant of fast track designation for SLS-005 (IV trehalose) for the treatment of spinocerebellar ataxia
8 November 2021 - Global Phase IIb/III study for SLS-005 to be initiated in early 2022.
Seelos Therapeutics announced today that the U.S. FDA has also granted the program fast track designation in the U.S. for SCA, and SLS-005 has previously received orphan drug designation for spinocerebellar ataxia type 3 (SCA3) from the FDA and from the European Medicines Agency in the EU.
